Tag: lung cancer diagnostic and screening market forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Lung Cancer Diagnostic And Screening Market Size Likely To Evolve From 2025 Through 2034?

The lung cancer diagnostic and screening market size has shown strong growth in recent years. It is anticipated to increase from $2.34 billion in 2024 to $2.56 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.4%. This historical growth can be ascribed to advancements such as the expansion of digital imaging, the standardization of screening protocols, public health initiatives targeting tobacco use, the establishment of cancer registries, and improvements in pathology analysis.

The market for lung cancer diagnostics and screening is anticipated to experience substantial expansion in the coming years. By 2029, it is projected to reach “$3.68 billion”, demonstrating a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period can be primarily attributed to factors such as the rising incidence of lung cancer, a heightened focus on early detection, the expansion of high-risk screening initiatives, the evolving trend towards personalized medicine, and various government initiatives and funding efforts. Significant trends anticipated in this period encompass the development of new screening methods, progress in biomarker testing, the incorporation of artificial intelligence (AI), an increase in the adoption of liquid biopsy, a concentrated effort on identifying cancer at early stages, and the broadening of low-dose CT screening programs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Are The Drivers Pushing New Developments In The Lung Cancer Diagnostic And Screening Market?

An anticipated rise in lung cancer cases is projected to boost the expansion of the lung cancer diagnostic and screening market in the coming years. This severe illness, marked by the uncontrolled multiplication of irregular cells within lung tissues, presents with indications like coughing, chest pain, and impaired breathing. Early detection of this condition in patients is facilitated by lung cancer diagnosis and screening, utilizing diverse procedures such as an incisional biopsy and a bronchoscopy. As an illustration, data from January 2023, released by the American Cancer Society, a US-based government organization, revealed approximately 238,340 new cases of lung cancer in the United States (comprising 117,550 in men and 120,790 in women). Additionally, 127,070 deaths attributed to lung cancer were reported (with 67,160 among men and 59,910 among women). Consequently, the increasing incidence of lung cancer is a key factor propelling the expansion of the lung cancer diagnostic and screening market.

What Are The Major Segments Identified In The Lung Cancer Diagnostic And Screening Market?

The lung cancer diagnostic and screeningmarket covered in this report is segmented –

1) By Product: Instruments; Consumables And Accessories

2) By Test: Biomarkers Tests; Imaging Test; Biopsy; Blood Test; Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer

4) By End User: Hospital; Independent Diagnostic Laboratories; Diagnostic Imaging Centers; Cancer Research Institutes; Other End-Users

Subsegments:

1) By Instruments: Imaging Devices; Biopsy Devices; Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles; Reagents And Assays; Imaging Contrast Agents; Patient Preparation Equipment; Sample Collection Kits; Laboratory Supplies

Which Ongoing Trends Are Expected To Shape The Lung Cancer Diagnostic And Screening Market Outlook?

Leading firms within the lung cancer diagnostic and screening sector are innovating technologies, including specific lung cancer tests, to improve early identification, refine diagnostic precision, and enable tailored treatment strategies for individuals highly susceptible to the illness. These lung cancer tests function as diagnostic tools, employing diverse methodologies such as imaging techniques, biomarker assessments, and cytological studies, to identify the existence of the disease. As an illustration, Freenome, a US biotechnology enterprise, introduced PROACT LUNG in December 2023. The PROACT LUNG trial offers a significant advancement set to transform lung cancer screening, with the potential to achieve earlier diagnoses and superior patient results, concurrently bridging current screening deficiencies.

Who Are The Key Multinational Companies Dominating The Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

What Are The Key Regional Factors Influencing The Lung Cancer Diagnostic And Screening Market Growth?

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2025, By The Business Research Company

Cold Chain Packaging Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-chain-packaging-global-market-report

Pharmaceutical Logistics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-logistics-global-market-report

Chemicals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemicals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Fast Is The Lung Cancer Diagnostic And Screening Market Expected to Grow Between 2025 And 2029?#_x000D_

The market for lung cancer detection and screening has expanded significantly in the past few years. The market is set to rise from $2.34 billion in 2024 to $2.56 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. Factors contributing to the historical growth include the rise in digital imaging, the standardization of screening procedures, public health campaigns targeting tobacco use, the creation of cancer registries, and advancements in pathological examination._x000D_

_x000D_

The market size for lung cancer diagnosis and screening is projected to witness robust growth in the forthcoming years, expected to achieve a value of$3.68 billion by 2029″, progressing at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth during the forecast period can be credited to the rising prevalence of lung cancer, growing focus on early diagnosis, development of screening programs for high-risk groups, shift towards individualized treatment, and government-initiated measures and financial support. Notable trends for the forecasted period encompass the introduction of innovative screening methods, progress in biomarker testing, the incorporation of artificial intelligence (AI), increased adoption of liquid biopsy, emphasis on the detection of early-stage cancer, and growth of low-dose CT screening programs._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Lung Cancer Diagnostic And Screening Industry?#_x000D_

The lung cancer diagnostic and screening market is projected to expand due to the rising incidence of lung cancer. Lung cancer is a lethal disease characterized by uncontrolled growth of anomalous cells in the lung tissues, causing symptoms such as coughing, chest pain, and trouble breathing. To aid early detection of the disease, lung cancer diagnosis and screening offer various tests, including an incisional biopsy and a bronchoscopy. As per the American Cancer Society, a governmental organization based in the United States, there were around 238,340 new lung cancer cases in January 2023 (117,550 in men and 120,790 in women). Moreover, approximately 127,070 fatalities were attributed to lung cancer (67,160 in men and 59,910 in women). Hence, the mounting prevalence of lung cancer is fueling the growth of the lung cancer diagnostic and screening market._x000D_

_x000D_

#How Is the Lung Cancer Diagnostic And Screening Market Segmented?#_x000D_

The lung cancer diagnostic and screeningmarket covered in this report is segmented – _x000D_

_x000D_

1) By Product: Instruments; Consumables And Accessories_x000D_

2) By Test: Biomarkers Tests; Imaging Test; Biopsy; Blood Test; Other Tests_x000D_

3) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer_x000D_

4) By End User: Hospital; Independent Diagnostic Laboratories; Diagnostic Imaging Centers; Cancer Research Institutes; Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Instruments: Imaging Devices; Biopsy Devices; Bronchoscopy Systems _x000D_

2) By Consumables And Accessories: Biopsy Needles; Reagents And Assays; Imaging Contrast Agents; Patient Preparation Equipment; Sample Collection Kits; Laboratory Supplies _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Lung Cancer Diagnostic And Screening Market Growth?#_x000D_

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Lung Cancer Diagnostic And Screening Industry?#_x000D_

Key players in the lung cancer diagnostic and screening market are innovating by creating technologies such as lung cancer examinations to boost early detection, enhance diagnostic precision, and offer personalized treatment options for patients susceptible to the disease. These lung cancer tests are diagnostic strategies developed to identify lung cancer by various means, such as imagery, biomarker evaluation, and cytological tests. For example, in December 2023, a biotech firm based in the United States, Freenome, introduced PROACT LUNG. The PROACT LUNG study signifies a hopeful breakthrough in transforming lung cancer screening, potentially enabling earlier detection and improved patient results, while filling in the existing deficiencies in current screening methods._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report_x000D_

_x000D_

#How Is the Lung Cancer Diagnostic And Screening Market Defined and What Are Its Core Parameters?#_x000D_

Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12043_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Lung Cancer Diagnostic And Screening Market Size Changed, over the years?

In recent times, the market size for lung cancer diagnosis and screening has seen a significant expansion. The market, projected to rise from $2.34 billion in 2024 to $2.56 billion in 2025, is set to have a compound annual growth rate (CAGR) of 9.6%. The former growth can be attributed to the influence of factors like the emergence of digital imaging, the standardizing of screening procedures, public health campaigns against tobacco consumption, the creation of cancer registries, and advancements in the field of pathology analysis.

How Much Will the Lung Cancer Diagnostic And Screening Market Be Worth in 2029?

In the coming years, it is anticipated that the market size of lung cancer diagnostics and screenings will experience robust growth. This growth is projected to reach a value of $3.69 billion by 2029, marking a compound annual growth rate (CAGR) of 9.5%. The projected growth during this forecast period is mainly due to factors such as an increase in lung cancer incidence, a growing concentration on early detection, the enlargement of high-risk screening programs, a move towards individualized medicine, and governmental support and funding. The forecast period is also expected to see major trends like the advent of innovative screening methods, advancements in biomarker testing, the incorporation of artificial intelligence (AI), a surge in the adoption of liquid biopsy, a focus on early stage detection, and an expansion of low-dose CT screening programmes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Which is the Largest Company in the Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

What Are the Main Market Drivers in the Lung Cancer Diagnostic And Screening Industry?

The anticipated growth of the lung cancer diagnostic and screening market is largely influenced by the rising occurrence of lung cancer. This aggressive disease, characterized by the unruly growth of abnormal cells in the lung tissues, manifests symptoms such as cough, chest pain, and difficulty in breathing. Lung cancer diagnosis and screening facilitate early detection of the disease, utilizing various tests such as the incisional biopsy and bronchoscopy. For example, the American Cancer Society, a governmental organization in the US, reported approximately 238,340 new lung cancer cases (comprising 117,550 men and 120,790 women) in January 2023. Furthermore, lung cancer claimed approximately 127,070 lives, with 67,160 men and 59,910 women. Consequently, the escalating incidence of lung cancer has been instrumental in fuelling the growth of the lung cancer diagnostic and screening market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

How Is the Lung Cancer Diagnostic And Screening Market Segments Structured?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Patient Preparation Equipment, Sample Collection Kits, Laboratory Supplies

What Strategic Trends Are Transforming the Lung Cancer Diagnostic And Screening Market?

Leading corporations in the domain of lung cancer diagnosis and screening are focusing on creating innovations such as tests for lung cancer. The goal is to foster early detection, boost the precision of diagnosis and enable individualized treatment plans for patients who are at an elevated likelihood of contracting the disease. Lung cancer screenings are diagnostic processes developed to reveal the existence of lung cancer utilizing a variety of methods encompassing imaging, analysis of biomarkers, and cytological tests. For example, in December 2023, Freenome, a biotech firm based in the US, introduced PROACT LUNG. This trial acts as a hopeful indication of transformative changes in lung cancer screening, potentially triggering faster detection and improved results for patients. It also aims to address present shortcomings in the existing screening protocols.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Global Regions Offer the Highest Growth in the Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12043

This Report Delivers Insight On:

1. How big is the lung cancer diagnostic and screening market, and how is it changing globally?

2. Who are the major companies in the lung cancer diagnostic and screening market, and how are they performing?

3. What are the key opportunities and risks in the lung cancer diagnostic and screening market right now?

4. Which products or customer segments are growing the most in the lung cancer diagnostic and screening market?

5. What factors are helping or slowing down the growth of the lung cancer diagnostic and screening market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the lung cancer diagnostic and screening industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Lung Cancer Diagnostic And Screening Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the market size for lung cancer diagnosis and screening has seen a significant expansion. The market, projected to rise from $2.34 billion in 2024 to $2.56 billion in 2025, is set to have a compound annual growth rate (CAGR) of 9.6%. The former growth can be attributed to the influence of factors like the emergence of digital imaging, the standardizing of screening procedures, public health campaigns against tobacco consumption, the creation of cancer registries, and advancements in the field of pathology analysis.

In the coming years, it is anticipated that the market size of lung cancer diagnostics and screenings will experience robust growth. This growth is projected to reach a value of $3.69 billion by 2029, marking a compound annual growth rate (CAGR) of 9.5%. The projected growth during this forecast period is mainly due to factors such as an increase in lung cancer incidence, a growing concentration on early detection, the enlargement of high-risk screening programs, a move towards individualized medicine, and governmental support and funding. The forecast period is also expected to see major trends like the advent of innovative screening methods, advancements in biomarker testing, the incorporation of artificial intelligence (AI), a surge in the adoption of liquid biopsy, a focus on early stage detection, and an expansion of low-dose CT screening programmes.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Lung Cancer Diagnostic And Screening Market?

The anticipated growth of the lung cancer diagnostic and screening market is largely influenced by the rising occurrence of lung cancer. This aggressive disease, characterized by the unruly growth of abnormal cells in the lung tissues, manifests symptoms such as cough, chest pain, and difficulty in breathing. Lung cancer diagnosis and screening facilitate early detection of the disease, utilizing various tests such as the incisional biopsy and bronchoscopy. For example, the American Cancer Society, a governmental organization in the US, reported approximately 238,340 new lung cancer cases (comprising 117,550 men and 120,790 women) in January 2023. Furthermore, lung cancer claimed approximately 127,070 lives, with 67,160 men and 59,910 women. Consequently, the escalating incidence of lung cancer has been instrumental in fuelling the growth of the lung cancer diagnostic and screening market.

Which Primary Segments of the Lung Cancer Diagnostic And Screening Market Are Driving Growth and Industry Transformations?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Patient Preparation Equipment, Sample Collection Kits, Laboratory Supplies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Lung Cancer Diagnostic And Screening Market?# Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Lung Cancer Diagnostic And Screening Market?

Leading corporations in the domain of lung cancer diagnosis and screening are focusing on creating innovations such as tests for lung cancer. The goal is to foster early detection, boost the precision of diagnosis and enable individualized treatment plans for patients who are at an elevated likelihood of contracting the disease. Lung cancer screenings are diagnostic processes developed to reveal the existence of lung cancer utilizing a variety of methods encompassing imaging, analysis of biomarkers, and cytological tests. For example, in December 2023, Freenome, a biotech firm based in the US, introduced PROACT LUNG. This trial acts as a hopeful indication of transformative changes in lung cancer screening, potentially triggering faster detection and improved results for patients. It also aims to address present shortcomings in the existing screening protocols.

View the full report here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

What Parameters Are Used to Define the Lung Cancer Diagnostic And Screening Market?

Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12043

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Lung Cancer Diagnostic And Screening Market?

The surge in lung cancer cases is projected to fuel the expansion of the lung cancer diagnostic and screening market. Characterized by uncontrolled growth of atypical cells in the lung tissues, lung cancer is a malicious disease that manifests symptoms such as persistent coughing, chest discomfort, and breathing difficulties. The diagnosis and screening for lung cancer enable patients to detect the illness early through various tests like incisional biopsy and bronchoscopy. Take for instance, in January 2023, the American Cancer Society, a US government organization, recorded roughly 238,340 new lung cancer cases (117,550 in men and 120,790 in women) in the United States. Moreover, an estimated 127,070 lung cancer related deaths were reported (comprising of 67,160 men and 59,910 women). Consequently, the escalating lung cancer incidence rate is stimulating the growth of the lung cancer diagnostic and screening market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

#What is the Growth Potential of the Lung Cancer Diagnostic And Screening Market, and How Will It Perform by 2034?

The market size for lung cancer diagnosis and screening has seen considerable growth in the recent years. The projections indicate that it will surge from $2.34 billion in 2024 to $2.56 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.6%. The unprecedented growth witnessed in the past years can be credited to factors such as advancements in digital imaging, standardization of screening procedures, anti-tobacco public health campaigns, the foundation of cancer registries, and progress in the field of pathology analysis.

The market size for lung cancer diagnostic and screening is forecasted to experience substantial growth within the next few years, expanding to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth across the forecast period is credited to the rising cases of lung cancer, increasing focus on early detection, more high-risk screening programs, the shift towards personalized medicine, and government initiatives with funding. Major trends within the forecast period encompass the appearance of new screening methods, advancements in biomarker testing, artificial intelligence (AI) integration, increase in liquid biopsy usage, concentration on early stage detection, and expansion of low-dose CT screening programs.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12043

What Are the Most Significant Market Trends Transforming theLung Cancer Diagnostic And Screening Market?

Prominent firms in the lung cancer diagnostic and screening market are advancing technologies such as lung cancer tests to boost early detection, enhance diagnostic precision, and promote personalized treatment protocols for patients likely to develop the disease. Lung cancer tests are diagnostic processes aimed at identifying lung cancer using multiple techniques, like imaging, biomarker assessment, and cytology tests. For instance, in December 2023, US-based biotech firm Freenome introduced PROACT LUNG. This trial of PROACT LUNG suggests a potentially transformative step in the field of lung cancer screening, which may facilitate early detection and improved patient results, while tackling current screening deficiencies.

What Are the Top Market Players Propelling the Growth of theLung Cancer Diagnostic And Screening Industry?

Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Primary Segments of the Lung Cancer Diagnostic And Screening Market Are Driving Growth and Industry Transformations?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Patient Preparation Equipment, Sample Collection Kits, Laboratory Supplies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Lung Cancer Diagnostic And Screening Market?# Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal Lung Cancer Diagnostic And Screening Maret 2025, By The Business Research Company:

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Personal Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/personal-services-global-market-report

Toiletries Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/toiletries-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted CAGR for the Lung Cancer Diagnostic And Screening Market Over the Forecast Period of 2025 to 2034?

The lung cancer diagnostic and screening market has expanded considerably in recent years. It is forecasted to grow from $2.34 billion in 2024 to $2.56 billion in 2025 at a CAGR of 9.6%. This growth has been driven by advancements in digital imaging, standardization of screening protocols, public health initiatives against tobacco consumption, establishment of cancer registries, and innovations in pathology analysis.

The lung cancer diagnostic and screening market is expected to expand considerably, reaching $3.69 billion by 2029 at a CAGR of 9.5%. Factors fueling this growth include a rising incidence of lung cancer, heightened focus on early detection, the expansion of high-risk screening initiatives, a shift toward personalized medicine, and government-backed funding efforts. Notable trends include new screening technologies, improvements in biomarker testing, AI integration, increased use of liquid biopsy, and expanded low-dose CT screening programs.

What Are the Primary Drivers Supporting the Growth of the lung cancer diagnostic and screening Market?

The growing incidence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market. Lung cancer, characterized by symptoms such as coughing and chest pain, requires early detection through methods like biopsies and bronchoscopies. In January 2023, the American Cancer Society reported 238,340 new cases and 127,070 deaths from lung cancer in the U.S. This increase in lung cancer cases will drive the demand for diagnostic and screening services.

Explore Comprehensive Insights Into The Global Lung Cancer Diagnostic And Screening Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Who Are the Top Companies Driving Innovation and Growth in the Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market include:

• Pfizer Inc._x000D_

• F. Hoffmann-La Roche AG_x000D_

• Bristol-Myers Squibb Company_x000D_

• Thermo Fisher Scientific Inc._x000D_

• AstraZeneca Plc_x000D_

What Key Trends Are Currently Impacting the Lung Cancer Diagnostic And Screening Market’s Development?

In the lung cancer diagnostic and screening market, companies are developing technologies like lung cancer tests to improve early detection, diagnostic accuracy, and personalized treatment options for high-risk patients. For example, in December 2023, Freenome, a US-based biotechnology company, launched the PROACT LUNG trial. This innovative lung cancer screening test aims to revolutionize early detection and improve patient outcomes while addressing the shortcomings of current screening methods.

Secure Your Global Lung Cancer Diagnostic And Screening Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

What Are the Key Components of the Lung Cancer Diagnostic And Screening Market, and How Do Its Segments Perform?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Patient Preparation Equipment, Sample Collection Kits, Laboratory Supplies

Which Geographical Regions Are Pioneering Growth in the Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Do Experts Define the Scope of the Lung Cancer Diagnostic And Screening Market?

Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

Browse Through More Similar Reports By The Business Research Company:

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Personal Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/personal-services-global-market-report

Toiletries Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/toiletries-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted CAGR for the Lung Cancer Diagnostic And Screening Market Over the Forecast Period of 2025 to 2034?

The lung cancer diagnostic and screening market has expanded considerably in recent years. It is forecasted to grow from $2.34 billion in 2024 to $2.56 billion in 2025 at a CAGR of 9.6%. This growth has been driven by advancements in digital imaging, standardization of screening protocols, public health initiatives against tobacco consumption, establishment of cancer registries, and innovations in pathology analysis.

The lung cancer diagnostic and screening market is expected to expand considerably, reaching $3.69 billion by 2029 at a CAGR of 9.5%. Factors fueling this growth include a rising incidence of lung cancer, heightened focus on early detection, the expansion of high-risk screening initiatives, a shift toward personalized medicine, and government-backed funding efforts. Notable trends include new screening technologies, improvements in biomarker testing, AI integration, increased use of liquid biopsy, and expanded low-dose CT screening programs.

What Are the Primary Drivers Supporting the Growth of the lung cancer diagnostic and screening Market?

The growing incidence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market. Lung cancer, characterized by symptoms such as coughing and chest pain, requires early detection through methods like biopsies and bronchoscopies. In January 2023, the American Cancer Society reported 238,340 new cases and 127,070 deaths from lung cancer in the U.S. This increase in lung cancer cases will drive the demand for diagnostic and screening services.

Explore Comprehensive Insights Into The Global Lung Cancer Diagnostic And Screening Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Who Are the Top Companies Driving Innovation and Growth in the Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market include:

• Pfizer Inc._x000D_

• F. Hoffmann-La Roche AG_x000D_

• Bristol-Myers Squibb Company_x000D_

• Thermo Fisher Scientific Inc._x000D_

• AstraZeneca Plc_x000D_

What Key Trends Are Currently Impacting the Lung Cancer Diagnostic And Screening Market’s Development?

In the lung cancer diagnostic and screening market, companies are developing technologies like lung cancer tests to improve early detection, diagnostic accuracy, and personalized treatment options for high-risk patients. For example, in December 2023, Freenome, a US-based biotechnology company, launched the PROACT LUNG trial. This innovative lung cancer screening test aims to revolutionize early detection and improve patient outcomes while addressing the shortcomings of current screening methods.

Secure Your Global Lung Cancer Diagnostic And Screening Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

What Are the Key Components of the Lung Cancer Diagnostic And Screening Market, and How Do Its Segments Perform?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Patient Preparation Equipment, Sample Collection Kits, Laboratory Supplies

Which Geographical Regions Are Pioneering Growth in the Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Do Experts Define the Scope of the Lung Cancer Diagnostic And Screening Market?

Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

Browse Through More Similar Reports By The Business Research Company:

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Personal Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/personal-services-global-market-report

Toiletries Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/toiletries-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: